New Launch29 Jul 2026, 10:10 pm
Sun Pharma Gets Brazil Approval for Semaglutide Injection
AI Summary
Sun Pharmaceutical Industries Limited has received approval from Brazil's ANVISA to manufacture and market semaglutide injection. This drug is used for type 2 diabetes management. Sun Pharma plans to launch the product in Brazil within days, in partnership with Hypera Pharma. The product will be available as a pre-filled, multi-dose injectable pen in two strengths, offering a once-weekly dosing regimen. The Brazilian semaglutide injectable market is valued at approximately USD 413 million.
Key Highlights
- Sun Pharma receives ANVISA approval for semaglutide in Brazil.
- Product targets type 2 diabetes treatment, expanding diabetes portfolio.
- Partnership with Hypera Pharma for market launch.
- Brazilian semaglutide market estimated at USD 413 million.
- Enhances global access to diabetes treatment options.
Price Impact
More from SUNPHARMA